Puyi (Shanghai) Biotechnology Co., Ltd. (‘Puyi Biotech’ or ‘Company’) is located in the Zhangjiang Hi-Tech Park in Shanghai China. Leveraging its knowhow in biomedical material science and its proprietary drug-eluting technology, Puyi Biotech and its subsidiaries have developed an innovative R&D pipeline of high-end implantable therapeutics. Independently developed ‘BISORB Drug-Eluting Sinus Absorbable System’ has obtained a product registration certificate through the special approval channel for national innovative medical devices. It is the first domestically approved fully degradable nasal sinus product, listed in the ‘Innovative Medical Device Product Catalog (2018)’ as an ‘international originality’. Corina Intrauterine Drug-Eluting System (‘Corina’), developed by Yipurun (Shanghai) Biotechnology Co., Ltd. (a wholly-owned subsidiary of Puyi Biotech, ‘YPR’), has received approval in China (G.X.Z.Z. 20243181461) for use in patients with moderate-to-severe intrauterine adhesions (IUA), who undergo transcervical resection of adhesions (TCRA). The approval for this indication is based on a randomized controlled clinical trial that demonstrated Corina’s superior efficacy compared to the standard-of-care. Corina is a first-in-class treatment focused on promoting female reproductive health through the prevention of intrauterine re-adhesion risk post TCRA, and the improvement of endometrial growth. Puyi Biotech and its subsidiaries own more than 100 domestic patents and 40 international patents across different areas of innovation. We are dedicated to providing innovative solutions to address unmet clinical needs across women’s health, ENT (ear, nose and throat), and medical aesthetics categories.
ABOUT US
